XORTX Therapeutics Inc
XTSX:XRTX
XORTX Therapeutics Inc
XORTX Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-09-30. The firm is focused on identifying, developing and commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD) and type 2 diabetic nephropathy (T2DN) as well as acute kidney injury (AKI) due to coronavirus infection. Its lead product candidates are XRx-008, XRx-101 and XRx-225. XRx-008 is a late clinical stage program focused on demonstrating the potential of its therapy for ADPKD. XRx-101 is a program to treat acute kidney injury associated with Coronavirus/ COVID-19 infection, AKI and associated health consequences. XRx-225 is a program for the treatment of T2DN. The company is also working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid.
XORTX Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-09-30. The firm is focused on identifying, developing and commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD) and type 2 diabetic nephropathy (T2DN) as well as acute kidney injury (AKI) due to coronavirus infection. Its lead product candidates are XRx-008, XRx-101 and XRx-225. XRx-008 is a late clinical stage program focused on demonstrating the potential of its therapy for ADPKD. XRx-101 is a program to treat acute kidney injury associated with Coronavirus/ COVID-19 infection, AKI and associated health consequences. XRx-225 is a program for the treatment of T2DN. The company is also working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid.
